Effects of a high-fat meal on the relative oral bioavailability of piperaquine
about
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditMulti-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with ElectrocardiogramsPopulation Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT intervalInterspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsRole of P glycoprotein in absorption of novel antimalarial drugs.Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.A small amount of fat does not affect piperaquine exposure in patients with malaria.Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical AssessmentPopulation pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study.Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malariaPharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria.Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria.Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.Piperaquine Population Pharmacokinetics and Cardiac Safety in Cambodia.Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.Use of quantitative pharmacology tools to improve malaria treatments.Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population.Single dose treatment of malaria - current status and perspectives.The application of physiologically-based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin.Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects.
P2860
Q21032449-931C6681-6B42-4251-B859-6BEB635E72E8Q28552793-75395222-BAA3-4D50-A20C-8715F25277C8Q31153944-575A9311-C83C-4441-A9E4-FF56616AF1D0Q33276757-EFA301CB-41DA-4C61-B17D-C025F384B64BQ33298467-D0BB8CC9-3CAF-475E-A827-3AFBB092A035Q33516563-FDF5F4A5-8B1C-4F99-B19C-6FF313FA77B1Q33622892-C63D6CC7-0A44-4427-8A28-A8D4C93F992EQ33903438-76542F08-1D5D-4331-BE0D-8509889B4DB1Q34160147-911A8278-D44C-455C-AD46-A10C555CA049Q34298973-C68C01D8-B639-48BA-8295-3EB18D28A937Q34299078-0CF35C77-1B09-4594-9E9C-3E4E2CD612ACQ34299178-A11AFAD2-8044-451E-9B88-35A251579FBEQ34597891-CFCF36AC-95A8-4F51-8164-8A200AC72855Q35055212-EE51549C-5651-4067-BEAD-7F56C7886132Q35091572-27BF5D5C-AE07-44A6-AB92-189C7607B10BQ35139505-8A61F4D4-B449-47AB-B57F-08BF887698BAQ35191426-B09F55C9-2895-4E7C-A775-F9A2C38D4FF9Q35598379-0E2F331D-245D-4010-ADA0-5EA6908A3F76Q35746240-6CCF0BBB-92BC-4D4F-B9DF-14BDC0D55538Q35806356-5D183E88-AA69-4D7D-BAC9-81FE939FC418Q35859839-93F5C664-1186-46CC-9577-FA7C31CFBB4EQ35867343-923F634D-BF5F-428E-AEF1-45A9DC685ECFQ35941440-7D96FF46-F707-4370-B24D-7B7EBB53A034Q36018642-0B745482-3E2E-4ADD-BE40-68CB6B38CA1DQ36080121-F419A753-0897-413A-AE44-EB720E72B3C4Q36422652-E811C987-6FFA-4CE9-82A2-92D5C84039BEQ36422706-3B98CD9F-F1BE-4130-A589-2D8CAD44318AQ36482878-24553EB1-85A0-4D30-AF80-594B943C1C45Q36552289-F3E5F784-D38F-45D5-908D-A74CD0288B04Q37038270-979DC097-90A0-4CBA-AD2F-9450470FC618Q37077284-DA9C04D9-5445-49A9-96BD-E3D80D8796A9Q37383670-92BD8198-0D1D-409B-BED9-3F180CD3ABB5Q38380902-25B5E15E-D345-4F22-8BAE-04342ED7A166Q38627882-CC1581B7-E15F-4FCC-A68B-DABA3701E3F5Q38664529-40988B54-9D3E-49B1-A88D-B44258FD1F81Q38815307-43C7E765-DD68-4C7A-A941-F111A14F1C95Q39253978-3F7DBE8B-08B7-49AC-AE03-C66CFC4F9C79Q40133890-AD67FEB8-A539-4842-99AA-744FFD40E3CDQ41040998-416C01C7-ED66-48F9-A296-D789F61BB3E6Q41938142-2BA23ACF-C278-4F93-B08A-AF81C7E6AB9F
P2860
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
@ast
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
@en
type
label
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
@ast
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
@en
prefLabel
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
@ast
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
@en
P2860
P1476
Effects of a high-fat meal on the relative oral bioavailability of piperaquine
@en
P2093
Ing-Kye Sim
Kenneth F Ilett
P2860
P304
P356
10.1128/AAC.49.6.2407-2411.2005
P407
P577
2005-06-01T00:00:00Z